Get notified when NMRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeumora Therapeutics reports Q4 and full-year 2025 financial results
Filed March 30, 2026 · Period ending March 30, 2026 · ~1 min read
Key Changes
-
medium
Company announced fourth quarter and full-year 2025 financial results on March 30, 2026. Specific financial metrics and performance details are contained in the accompanying press release.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings disclosure filing. The 8-K itself contains no financial details; all results are in the attached press release exhibit.
8-K: Earnings verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade NMRA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify